THX Pharma (STU:3VG) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:3VG THX Pharma STU:3VG
39 GF Score
Price €3.66
! 2 Warning Signs
View Full Analysis

What is THX Pharma 5-Year Yield-on-Cost %?

THX Pharma STU:3VG -3.30% 39 5-Year Yield-on-Cost % is 0.00 as of Jul. 17, 2026. GuruFocus rates STU:3VG with a GF Score™ of 39/100. The stock has 2 warning signs investors should review. Among 152 Biotechnology companies, THX Pharma ranks worse than 657894.08% on this metric.

THX Pharma's yield on cost for the quarter that ended in Dec. 2025 was 0.00.


The historical rank and industry rank for THX Pharma's 5-Year Yield-on-Cost % or its related term are showing as below:



STU:3VG's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.73
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

THX Pharma  (STU:3VG) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


THX Pharma 5-Year Yield-on-Cost % Related Terms


STU:3VG vs VRTX, REGN, ALNY: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, THX Pharma's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


THX Pharma 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, THX Pharma's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where THX Pharma's 5-Year Yield-on-Cost % falls into.


STU:3VG
39GF Score
THX Pharma STU:3VG
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

THX Pharma 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of THX Pharma is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
THX Pharma (STU:3VG) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 17, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on THX Pharma and its competitors. According to the industry distribution chart, THX Pharma ranks #999999 out of 152 companies in the Biotechnology industry.
Is THX Pharma's 5-Year Yield-on-Cost % too high?
THX Pharma's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, THX Pharma ranks #999999 out of 152 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, THX Pharma has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does THX Pharma's 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, THX Pharma ranks #999999 out of 152 companies for 5-Year Yield-on-Cost %. This places THX Pharma in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.73. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.73, based on 152 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on THX Pharma and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. THX Pharma's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is THX Pharma stock overvalued right now?
THX Pharma (STU:3VG) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. THX Pharma's overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For THX Pharma (STU:3VG), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

THX Pharma Business Description

Other Exchanges ALTHX:France
Address 60 avenue Rockefeller, Pepiniere Laennec, Lyon, FRA, 69008
THX Pharma Formerly Theranexus SA is a France based biopharmaceutical company. It is engaged in developing drug candidates to be used in the treatment of central nervous system (CNS) disorders. The company's therapeutics platform is based on simultaneously targeting neurons and glial cells by creating and developing innovative combinations of two distinct drugs: a CNS drug targeting neuronal activity; and a drug targeting glial cells. The drug candidates of the organization are THN102 to treat excessive daytime sleepiness in Parkinson's disease, THN201 for the treatment of neurocognitive disorders in Alzheimer's disease and THN101 for neuropathic pain.
39GF Score

Get the complete analysis for STU:3VG

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.66
Price